Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | NRXP |
---|---|---|
09:32 ET | 524 | 1.68 |
09:36 ET | 400 | 1.695 |
09:38 ET | 554 | 1.71 |
09:39 ET | 7798 | 1.7075 |
09:43 ET | 200 | 1.7003 |
09:48 ET | 2500 | 1.7 |
09:52 ET | 1845 | 1.6908 |
09:59 ET | 300 | 1.6806 |
10:01 ET | 1052 | 1.68 |
10:08 ET | 908 | 1.68 |
10:24 ET | 222 | 1.6813 |
10:30 ET | 1200 | 1.69 |
10:33 ET | 400 | 1.7 |
10:35 ET | 340 | 1.7004 |
10:48 ET | 632 | 1.71 |
11:02 ET | 1371 | 1.71 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
NRX Pharmaceuticals Inc | 18.3M | -1.1x | --- |
Protext Mobility Inc | 18.5M | 0.0x | --- |
Minerva Neurosciences Inc | 19.0M | -0.6x | --- |
Biomx Inc | 19.1M | -2.4x | --- |
Cocrystal Pharma Inc | 17.4M | -1.0x | --- |
Biora Therapeutics Inc | 19.5M | -0.1x | --- |
NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). The Company has two lead compounds, NRX-100, a proprietary presentation of ketamine and NRX-101, a fixed-dose combination of D-cycloserine (DCS) and lurasidone. The Company is developing NRX-101, a Food and Drug Administration (FDA)-designated investigational therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRX-101 is a combined NMDA/5-HT2A-targeted medicine designed to address both depression and suicidal ideation, consisting of an oral, fixed dose combination of DCS and lurasidone. Its NRX-100 is racemic ketamine, which is a generic anesthetic. The Company is also engaged in the development of its new product, NRX-102.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $18.3M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 10.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.25 |
EPS | $-1.62 |
Book Value | $-0.14 |
P/E Ratio | -1.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.